ScholarIQanswers from OpenAlex & ORCID
Narikazu Boku
ResearcherPublications, citations & collaboration network
Narikazu Boku is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Narikazu Boku have?
ScholarIQindexed works
Narikazu Boku has 809 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Narikazu Boku have?
ScholarIQcitation count
Narikazu Boku has 29,869 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Narikazu Boku?
ScholarIQh-index
Narikazu Boku has an h-index of 76 in OpenAlex.
What is the i10-index of Narikazu Boku?
ScholarIQi10-index
Narikazu Boku has an i10-index of 337 in OpenAlex.
What is the ORCID of Narikazu Boku?
ScholarIQorcid
The ORCID for Narikazu Boku is on the source record.
What is the OpenAlex record for Narikazu Boku?
ScholarIQopenalex
The OpenAlex for Narikazu Boku is on the source record.
What are the most-cited papers on Narikazu Boku?
ScholarIQmost cited works
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
Japanese Society for Cancer of the Colon and Rectum, Toshiaki Watanabe, Kei Muro, Yoichi Ajioka, Yojiro Hashiguchi, Yoshinori Ito, Yutaka Saito, Tetsuya Hamaguchi, Hideyuki Ishida, Megumi Ishiguro, Soichiro Ishihara, Yukihide Kanemitsu, Hiroshi Kawano, Yusuke Kinugasa, Norihiro Kokudo, Keiko Murofushi, Takako Eguchi Nakajima, Shiro Oka, Yoshiharu Sakai, Akihito Tsuji, Keisuke Uehara, Hideki Ueno, Kentaro Yamazaki, Masahiro Yoshida, Takayuki Yoshino, Narikazu Boku, Takahiro Fujimori, Michio Itabashi, Nobuo Koinuma, Takayuki Morita, Genichi Nishimura, Yuh Sakata, Yasuhiro Shimada, Keiichi Takahashi, Shinji Tanaka, Osamu Tsuruta, Toshiharu Yamaguchi, Naohiko YAMAGUCHI, Toshiaki Tanaka, Kenjiro Kotake, Kenichi Sugihara
Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)
Katsuhiko Uesaka, Narikazu Boku, Akira Fukutomi, Yukiyasu Okamura, Masaru Konishi, Ippei Matsumoto, Yuji Kaneoka, Yasuhiro Shimizu, Shoji Nakamori, Hirohiko Sakamoto, Soichiro Morinaga, Osamu Kainuma, Koji Imai, Naohiro Sata, Shoichi Hishinuma, Hitoshi Ojima, Ryuzo Yamaguchi, Satoshi Hirano, Takeshi Sudo, Yasuo Ohashi
Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study
Hideki Ueno, Tatsuya Ioka, Masafumi Ikeda, Shinichi Ohkawa, Hiroaki Yanagimoto, Narikazu Boku, Akira Fukutomi, Kazuya Sugimori, Hideo Baba, Kenji Yamao, T Shimamura, Masayuki Sho, Masayuki Kitano, Ann‐Lii Cheng, Kazuhiro Mizumoto, Jen‐Shi Chen, Junji Furuse, Akihiro Funakoshi, Takashi Hatori, Taketo Yamaguchi, Shinichi Egawa, Atsushi Satō, Yasuo Ohashi, Takuji Okusaka, Masao Tanaka
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)
Narikazu Boku, Min‐Hee Ryu, Ken Kato, Hyun Cheol Chung, Keiko Minashi, K.-W. Lee, H. Cho, Won Ki Kang, Yoshito Komatsu, Masahiro Tsuda, Kensei Yamaguchi, Hiroki Hara, Soichi Fumita, Mizutomo Azuma, L.-T. Chen, Yoon‐Koo Kang